This article was originally published in Start Up
Executive SummaryClearant Inc. eventually aims to apply its gamma pathogen inactivation technology to the blood transfusion market, but it is starting with sterilization of tissue implants and other biological products where the regulatory hurdles are lower and the timeline to commercialization is shorter.
You may also be interested in...
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)
We nominated 15 deals in three categories. You picked the winners.